ClinicalTrials.gg
CompletedNCT01390649Updated Apr 8, 2016Results posted

A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP)

A Phase 4 interventional study of IgPro10 in Immune Thrombocytopenic Purpura, sponsored by CSL Behring. Completed at 17 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-04-08.

Sponsored by CSL Behring (part of CSL Limited) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
57
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Romania — 5 open to participants now, 8 under way, 6 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Romania.

Enrollment
13th of 17
57 · median 99
Started
2011
the only one that year
Phase 4
2 of 17
none open now
Registered
4th of 17
by date
Lead sponsor
1 of 17
CSL Behring

Among the 17 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Romania, this one is the 13th largest by enrollment, is the only one that started in 2011, is one of 2 in phase 4, and was the 4th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

5 of the 17 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Romania are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Romania have not opened yet or have stopped. Only those recruiting at a site in Romania →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Romania, or all of them as a file.
02

Study summary

It is known that intravenous immunoglobulins can induce hemolysis, but the mechanism is not known in detail. The primary objective of this study was to investigate the specificity of antigens on red blood cells in patients with chronic immune thrombocytopenic purpura (ITP) who have shown signs of clinically relevant hemolysis following treatment with the intravenous immunoglobin Privigen®. The study was to explore potential mechanisms of hemolysis by analysis of the specificity of the antibodies possibly involved. To distinguish between clinically non-relevant hemolysis and a relevant intravascular hemolysis, an independent adjudication by a committee was performed for each patient with signs of hemolysis determined in the laboratory or in the clinic.

This study was requested as a post-marketing commitment study by the United States Food and Drug Administration (FDA). By September 2014, no case of clinically significant intravascular hemolysis was found, and the FDA agreed to halt the study and analyze all hemolysis-relevant endpoints using FDA criteria for hemolysis in addition to analyses planned in the protocol. The study was not restarted.

03

Conditions studied

  • Immune Thrombocytopenic Purpura

Keywords

  • ITP
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of chronic ITP
  • Age of 18 to 65 years
  • count of ≤ 30 x 10\^9/L at screening

Exclusion criteria

Exclusion Criteria:

  • Planned splenectomy throughout the study period
  • Treatment with immunoglobulin G for intravenous administration (IVIG) or anti-D immunoglobulin within 3 weeks prior to screening
  • Use of drugs that have any pharmacological effect on the blood clotting system within 3 weeks prior to screening
  • Known allergy or other severe reactions to blood products including intolerability to previous IVIG
  • Known hyperprolinemia
  • Red blood cell transfusion or erythropoietin treatment within the last 14 days
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    IgPro10

    Biological: IgPro10

Interventions

  • BiologicalIgPro10

    IgPro10 will be administrated by IV infusion either a single dose of 1 g/kg bw on 1 day or 2 doses of 1 g/kg bw on 2 days (2 g/kg bw total dose) dependent on the response to the first treatment.

    Also known as: Privigen

06

What researchers measure

Primary outcomes

  1. Set of Antibodies Most Frequently Bound to Red Blood Cells (RBCs) in Subjects Experiencing Clinically Significant Intravascular Hemolysis

    The occurrence of clinically significant intravascular hemolysis was determined by an independent Adjudication Committee. No subject experienced clinically significant intravascular hemolysis; therefore, the primary safety endpoint could not be analyzed.

    Time frame: Within 3 days of infusion

Secondary outcomes

  1. Responder Rate

    The responder rate is the percentage of subjects who have a platelet response (defined as a platelet count increase at least once to ≥ 50 x 10\^9/L after the first IgPro10 administration).

    Time frame: Within 6 days after the first infusion

07

Results

Posted Oct 19, 2015

Participant flow

Participant flow — Overall Study
MilestoneIgPro10
Started57
Completed56
Not completed1
Withdrew: Physician decision1

Outcome measures

PrimarySet of Antibodies Most Frequently Bound to Red Blood Cells (RBCs) in Subjects Experiencing Clinically Significant Intravascular Hemolysis

The occurrence of clinically significant intravascular hemolysis was determined by an independent Adjudication Committee. No subject experienced clinically significant intravascular hemolysis; therefore, the primary safety endpoint could not be analyzed.

Time frame:
Within 3 days of infusion

No measurements were reported for this outcome.

SecondaryResponder Rate

The responder rate is the percentage of subjects who have a platelet response (defined as a platelet count increase at least once to ≥ 50 x 10\^9/L after the first IgPro10 administration).

Time frame:
Within 6 days after the first infusion
Reported as:
Number · percentage of participants
Responder Rate
percentage of participantsIgPro10
Responder Rate74 (61 to 83)

Adverse events

Collected over For the duration of individual subject participation in the study, up to approximately 35 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IgPro10—1/57 (1.8%)19/57 (33.3%)
Most frequent serious events
Most frequent serious events
EventIgPro10
Immune Thrombocytopenic PurpuraBlood and lymphatic system disorders1/57
Most frequent other events
Most frequent other events
EventIgPro10
HeadacheNervous system disorders17/57
PyrexiaGeneral disorders3/57

Baseline characteristics

Subjects treated with Privigen

Age, Categorical
Age, Categorical(Participants)IgPro10
<=18 years0
Between 18 and 65 years55
>=65 years2
Age, Continuous
Age, Continuous(years)IgPro10
Mean43.5 ± 13.10
Sex: Female, Male
Sex: Female, Male(Participants)IgPro10
Female37
Male20
08

Study locations

17 sites
  • UMHAT "Dr. Georgi Stranski" Clinic of Haematology
    Pleven, Bulgaria
  • UMHAT "Sv. Georgi" Clinic of Haematology
    Plovdiv, Bulgaria
  • Tokuda Hospital
    Sofia, Bulgaria
  • Emergency Clinical County Hospital Baia Mare
    Baia Mare, Romania
  • Emergency Clinical County Hospital Brasov
    Brasov, Romania
  • Clinical Institute "Fundeni"
    Bucharest, Romania
  • Universitary Hospital
    Bucharest, Romania
  • Clinical City Hospital "Filantropia"
    Craiova, Romania
  • City Hospital Oradea
    Oradea, Romania
  • Emergency Clinical County Hospital Tg. Mures
    Tg. Mures, Romania
  • Emergency Clinical City Hospital Timisoara
    Timisoara, Romania
  • Oncomed SRL
    Timisoara, Romania
  • Salvo-San-Ciobanca SRL
    Zalau, Romania
  • Clinical Center of Serbia
    Belgrade, Serbia
  • Clinical Hospital Bezanijska Kosa
    Belgrade, Serbia
  • Clinical Hospital Zemun
    Belgrade, Serbia
  • Clinical Center Nis
    Nis, Serbia
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2011
First posted
Jul 11, 2011
Start
Nov 2011
Primary completionActual
Sep 2014
CompletionActual
Sep 2014
Results first posted
Oct 19, 2015
Last update
Apr 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01390649
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Jul 11, 2011
Start date
Nov 2011
Primary completion
Sep 2014
Completion
Sep 2014
Results posted
Oct 19, 2015
Last update
Apr 8, 2016

Study contacts

Wieslaw Jedrzejczak
principal investigator · Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IGPRO10

Start the discussion